- Home
- CTEV vs CKPT Comparison
CTEV vs CKPT Comparison
Compare CTEV & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTEV
- CKPT
- Stock Information
- Founded
- CTEV 1980
- CKPT 2014
- Country
- CTEV United States
- CKPT United States
- Employees
- CTEV N/A
- CKPT N/A
- Industry
- CTEV
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- CTEV
- CKPT Health Care
- Exchange
- CTEV NYSE
- CKPT Nasdaq
- Market Cap
- CTEV 371.3M
- CKPT 335.9M
- IPO Year
- CTEV N/A
- CKPT 2017
- Fundamental
- Price
- CTEV $21.83
- CKPT $4.17
- Analyst Decision
- CTEV Hold
- CKPT Buy
- Analyst Count
- CTEV 1
- CKPT 3
- Target Price
- CTEV $19.00
- CKPT $4.33
- AVG Volume (30 Days)
- CTEV 53.5K
- CKPT 1.0M
- Earning Date
- CTEV 05-08-2025
- CKPT 05-16-2025
- Dividend Yield
- CTEV N/A
- CKPT N/A
- EPS Growth
- CTEV N/A
- CKPT N/A
- EPS
- CTEV N/A
- CKPT N/A
- Revenue
- CTEV $927,446,000.00
- CKPT $41,000.00
- Revenue This Year
- CTEV $2.18
- CKPT $102,182.93
- Revenue Next Year
- CTEV $3.04
- CKPT $351.71
- P/E Ratio
- CTEV N/A
- CKPT N/A
- Revenue Growth
- CTEV N/A
- CKPT N/A
- 52 Week Low
- CTEV $4.80
- CKPT $1.47
- 52 Week High
- CTEV $31.00
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- CTEV N/A
- CKPT 71.99
- Support Level
- CTEV N/A
- CKPT $4.02
- Resistance Level
- CTEV N/A
- CKPT $4.17
- Average True Range (ATR)
- CTEV 0.00
- CKPT 0.03
- MACD
- CTEV 0.00
- CKPT -0.01
- Stochastic Oscillator
- CTEV 0.00
- CKPT 93.33
About CTEV CLARITEV CORPORATION
Claritev Corp is a healthcare technology, data, and insights company focused on improving transparency, affordability, and quality. The company provides tech-enabled solutions and services to interpret clients' needs and customize solutions that combine its payment integrity, network-based, and analytics-based services. The Company's focus is being a value-added provider of data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the U.S. healthcare industry.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.